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This introductory article has been written in the form of a conversation between Pier Paolo
Pandolﬁ, Director of the Cancer Center of Beth Israel Deaconess Medical Center in Boston,
and Rosa Bernardi, a former post-doctoral fellow in the laboratory of Dr. Pandolﬁ, now prin-
cipal investigator at San Raffaele Scientiﬁc Institute in Milan, Italy. We have chosen this
atypical review format because we want to offer to our readers a more direct and personal
perspective on the ﬁrst 20years of research over the promyelocytic leukemia gene. This
article begins as an interview, but soon transforms into a dialog where we exchange our
thoughts on a number of issues around the past, present, and future research over the
biology of PML.We were particularly keen on emphasizing the aspects that we ﬁnd most
interesting or challenging, therefore, we warn our readers that this will not be a compre-
hensive essay but rather a very personal view of what has been, is, and will be exciting
and interesting in the PML world, in our opinion.
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INTRODUCTION
The promyelocytic leukemia gene,PML was originally discovered
becauseof itsinvolvementinacutepromyelocyticleukemia(APL)
(1–4),and was later shown to encode a homo-multimeric protein
withpredominantnuclearlocalization,widetissueexpression,and
prevalenttumorsuppressivefunctions,bothinhematologicaland
solid malignancies (Figure1).
Twenty years of intense research activity carried out by a
number of laboratories and prompted by the generation of Pml
knock-out (KO) mice (5), have led to the description of PML
as a widely multifaceted protein that regulates many aspects of
normal physiology and pathology (Figure 1). Complexity is the
term that best deﬁnes PML at many levels: the PML gene under-
goesmultiplealternativesplicingprocessesandgeneratesavariety
of PML mRNA species and protein isoforms; PML isoforms dif-
fer in a number of features, from protein interaction capabilities
and sub-cellular localization to speciﬁc functions within the cell;
PML functions are often subtle, and unveiled only upon speciﬁc
experimental challenges; the biochemistry of PML interactions is
particularly difﬁcult to tackle because of the insolubility of PML
proteincomplexes.Regardlessof thesedifﬁculties,orperhapspre-
cisely because of them,the study of PML functions has constantly
attracted the attention of many researchers. Such keen interest
had led over the years to the incessant addition of new levels of
complexity to the biology of PML. Reconciling everything that is
currently known into a unifying working model is at the present
time impossible, and probably unnecessary. For this reason, we
have chosen to freely discuss about what we ﬁnd most interest-
ing and promising about research on PML, beginning with a very
personal account on how it all started.
A DIALOG ON PML
Bernardi: Pier Paolo, in 1991 as a medical student to start with,
and a freshly graduated post-doctoral fellow in the laboratory of
Pier Giuseppe Pelicci (in those times leading his laboratory in
Perugia, now directing the Department of Experimental Oncol-
ogy at the European Institute of Oncology in Milan, Italy), you
cloned and characterized the PML transcript and its aberrant ver-
sion PML–RARa. This new genetic locus had been identiﬁed a
year earlier at the breakpoint of t(15;17) translocation along with
theretinoicacidreceptoragene(RARa)inAPLthroughthework
of Letizia Longo and yourself in the Pelicci laboratory, as well as
by other groups (6–8). You told me once that cloning and char-
acterizing the PML gene was a tough race; one of those exciting
and hysterical moments in science when you know that like you
other people, in other laboratories, are working day and night to
publish their results ﬁrst. Out of this race, within a time frame
of a few months, four papers described the characterization of
the PML gene [renamed PML after having been identiﬁed as Myl
(6)] and the PML–RARa fusion protein (1–4). This project must
have changed your life, and unquestionably shaped your career:
out of this line of research came your ﬁrst KO mouse and your
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Timeline: important events in PML research 
1990
Discovery of a 
new genetic 
locus at the 
t(15;17) 
breakpoint in 
APL
1991 1998 2000 2008 2004
Cloning and 
characterization of the 
PML gene (previously 
identified as Myl)
Generation of 
Pml knock-out 
mice. 
First indication 
of PML tumor 
suppressive 
functions
1993
Characterization 
of the sub-
cellular 
localization of 
PML into PML-
NBs
Characterization 
of the first 
function of 
cytoplasmic 
PML in TGF-  
signaling
Initial discovery 
of p53 
regulation by 
PML
First reporting 
that PML 
regulates stem 
cell behavior
2006
Discovery of 
PML 
regulation of 
the PI3K/
Akt/mTOR 
pathway
First indication 
that PML exerts 
oncogenic 
functions
2010
Identification of a 
pro-apoptotic function 
of PML at the 
mitochondria-
associated membranes 
of the ER  
1999
PML is essential 
for the 
formation of 
PML-NBs
FIGURE 1 |Timeline of the milestone discoveries on PML.
longstanding interest for leukemia gene rearrangements, which
later widened to include a larger spectrum of projects on the
genetic bases of cancer. What do you recall of those early days?
What have been the most exciting or frustrating moments?
Pandolﬁ: In those times, I had just begun working in a labo-
ratory as a medical student and as a summer student after a few
yearsofthrillingphilosophystudiesattheUniversityofRome,and
everythingaboutscienceandresearchwasverynovelandexciting.
Furthermore, the idea of cancer oncogenes really intrigued me.
The opportunity of being involved in such an ambitious project,
the cloning of a new cancer gene was from the get go pure adrena-
line. However, I will never forget when we obtained the ﬁrst PML
mRNA sequence and attempted to ﬁnd an open reading frame
that would mean something structurally: nothing! It was a big
disappointment. Now we know that PML has an RING domain
embedded into an RBCC or TRIM structure (9, 10), but at that
timeRINGﬁngerswerenotcharacterized.Wewerethereforereally
in the dark. But the ﬁrst antibody raised to recognize PML gave
thewholeAPLﬁeldsomehope.Wewereseeingnucleardots,what
we now call in jargon the PML-nuclear bodies [PML-NBs; Ref.
(11)]. This was indeed intriguing. But the real question that was
not making me sleep at night was whether PML was an onco-
gene,or else,and whether it would be important in the control of
hemopoiesis.
Bernardi: On my side, what I found most remarkable when I
begunworkingonPMListhebeautyofitssub-cellularlocalization
into the PML-NBs. These distinctive macromolecular structures
had been known to exist since the 60s (12), but only in 1993 they
were identiﬁed as sites of accumulation of PML, being renamed
at that point PML-nuclear bodies (13). We now know a lot of
things about PML-NBs: they are donut-shaped, with a diameter
of 0.2–1.0mm,thereisanaverageof 5–15of thempercellnucleus,
and they are formed by a ring of proteins surrounding an empty
space [sometimes occupied by microgranular material proposed
toberibonucleoproteins(12),withDNAandRNAlocalizingatthe
periphery of the ring (14, 15)]. However, it seems to me that even
though we have learnt a lot about their biochemistry and func-
tion,muchstillremaintobeuncovered.Forinstance,althoughwe
keep referring to them as PML-NBs,as if they were homogeneous
structures, in reality they probably are not: they vary in dynam-
ics, biochemistry, and structure in the different phases of the cell
cycle [with mitotic PML aggregates being so peculiar to have been
termed mitotic accumulations of PML protein, or MAPPs (16)],
in different cell types (i.e., embryonic stem cells versus cell lines),
and upon different types of cellular stresses, such as heat shock
or inhibition of transcription (12). However, besides a general
recognition that there may be different types of PML-NBs, a pre-
cise characterization of their speciﬁc structure and function is far
from being revealed.
I am also wondering whether a better characterization of PML
protein isoforms may help us to better characterize different types
of PML-NBs.Indeed,oneotherstrikingfeatureof PMListhehigh
number of alternatively spliced mRNA molecules and protein iso-
forms that are generated from the PML gene. All PML isoforms
contain the N-terminal homo-multimerization domain [termed
RBCC or TRIM (9,10)] that allows formation of high order mol-
ecular structures, but differ in their C-terminal regions (10), and
when expressed individually in Pml null cells form morphologi-
cally and dynamically different PML-NBs (17, 18). This suggests
that PML isoforms may play different roles in the formation and
maintenance of PML-NBs. However, in the absence of a compre-
hensive mapping of the relative expression of PML isoforms and
the relative composition of PML-NBs in different cell conditions,
thebiologicalrelevanceof PMLisoforms’speciﬁcityandtheirreg-
ulation of PML-NBs still remains to be established. I think that
this is a very interesting ﬁeld of research, where we should invest
more;especiallyconsideringthatspeciﬁcPMLisoformshavebeen
suggested to have exclusive functions (19).
Pandolﬁ: Talking about PML isoforms and isoform speciﬁcity,
whathasbeenoverlookedforawhileandonlyrecentlyhasstarted
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to be seriously investigated is the role of cytoplasmic PML iso-
forms and functions. Although aggregates of PML are visualized
mostly in the nucleus, we have known for a long time that a
number of PML splicing isoforms come into a cytoplasmic ﬂavor
through exclusion of exon 6 (that contains a nuclear localization
signal) (10–19). Also PMLI, the most abundant isoform, is both
nuclear and cytoplasmic due to a nuclear export signal in its C-
terminus,and even in the nucleus it is probably most abundant in
the nucleoplasm rather that in the bright PML-NBs (19). To me,
the identiﬁcation of novel functions of PML in the cytoplasm has
been among the most exciting recent advances of PML research.
Interestingly, similar to what we see in the nucleus, also in the
cytoplasmPMLappearstobeinvolvedinamultitudeofmolecular
functions: it activates TGF-b signaling by promoting the associa-
tionof TGF-breceptorswithSARAandSmadproteinsattheearly
endosome (20); it facilitates transfer of calcium to the mitochon-
dria and apoptosis by localizing at the mitochondria-associated
membranes of the endoplasmic reticulum (21); it interacts with
and suppresses the function of the M2 isoform of pyruvate kinase
(PKM2) thus suppressing tumor metabolism (22), even though
these ﬁndings are preliminary; and it regulates a number of
anti-viral responses (23).
Going back to the idea that different PML isoforms form dif-
ferent PML-NBs, one could imagine that function multiplicity
in the cytoplasm may also be explained by the presence of dif-
ferent cytoplasmic PML isoforms, although in the absence of a
moreprecisecharacterizationof isoforms’representation,thiscan
only be speculated at the moment. Alternatively, the speciﬁcity of
PML functions in the cytoplasm could be caused by its accumu-
lation into speciﬁc structures, such as endosomes or endoplasmic
reticulum, rather than by isoform speciﬁcity. In this respect, we
had observed that PML-induced stimulation of TGF-b signaling
could occur also upon expression of a truncated PML mutant
expressing only the N-terminal RBCC domain, and lacking any
C-terminal region in Pml null cells (20). In my view, a systematic
invivoanalysisinisoform-speciﬁcKOmodelsisverymuchneeded
and critically important; similarly important is the generation of
mouse mutant in which the PML-NBs could be visualized in their
in vivo dynamics. We are actively working on this.
Bernardi:With regard to the second point that you are making,
theideathattheregulationof PMLfunctionsmaydependconsid-
erably on its sub-cellular localization, this is further substantiated
bythenotionthatdynamicbehaviorsof PMLhavebeendescribed
also within the constraints of the cell nucleus. Indeed, I was quite
puzzled from the very ﬁrst experiment that I conducted in your
lab, as I was studying the regulation of p53 by PML in conditions
of DNAdamage,becauseIkeptobservingthatuponspeciﬁcDNA
damaging conditions, PML appeared to localize to an external
shellsurroundingthenucleolus(24).Previousstudieshadalready
described the localization of PML to the nucleolus upon inhibi-
tion of the proteasome (25). Interestingly, however, later studies
by the group of Hugues de Thé demonstrated that localization of
all PML isoforms to the nucleolus, or to aberrant nucleolar struc-
tures upon different kinds of cellular stress, is probably mediated
by PMLI, the most abundant PML isoform and the only one that
containsanucleolarlocalizationdomainhiddeninitsC-terminus
(26). This takes us back to the issue of isoform speciﬁcity.
In any case, regardless of the speciﬁcity of PML isoforms, as
suggested by the group of Hugues de Thé, the functional inter-
play between PML and the nucleolus must be quite important
as it recurs in a number of circumstances in which PML plays
an important role, ranging from the response to DNA damage to
cell senescence. Also, the C-terminal region of PMLI, which con-
tains the nucleolar-targeting domain, is the most evolutionarily
conserved (26).
Pandolﬁ: It is well possible that the nucleolar localization of
PML might be crucial to exert some of its functions. Certainly
though, not all that PML does go through the nucleolus. And
more generally, what remains difﬁcult to summarize for a general
audience is what exactly PML does in these various cellular sites,
and whether it exerts a speciﬁc enzymatic activity. The latter still
remains the key and most challenging question in the ﬁeld.
Fromahistoricalperspective,researchoverthefunctionofPML
has been greatly stimulated by the generation of Pml KO mice (5),
and the availability of primary cells lacking Pml expression. From
those early days on, through the work of many laboratories all
over the world, I think that the basic message that we have learnt
is that PML is a widely multifaceted protein that regulates many
important aspects of normal physiology and pathology. However,
PML functions are often subtle and unveiled only upon speciﬁc
experimental challenges. I still vividly remember the initial dis-
appointment when we discovered that Pml was dispensable for
embryonic life. I had moved to London to KO Pml in the mouse
after having read the seminal paper from Mario Capecchi and
colleagues describing the KO of the proto-oncogene int-2 [FGF3
(27)]. Those were early days, and the Pml KO mouse was one of
theﬁrstevergeneratedinEurope.Aftersomuchworktomakethe
Pml KOmouse,wewereimaginingthemostsevereof phenotypes,
andyetthiswasnotthecase:apparentlythemicewereﬁne.Inret-
rospect, though, we got our revenge in the years to follow. Since
then,many exiting functions of Pml were subsequently unraveled
by our group and others because of the Pml KO model.
Among the most important functions of PML, relevant to its
tumor suppressive activity is its ability to positively regulate the
function of p53 and family members, and negatively the PI3K
pathway,atmultiplelevels.Theregulationof p53byPMLwasone
of the ﬁrst functions of PML to be dissected in molecular detail
(28–30),andovertheyearshasbeenthemostextensivelyvalidated:
literature over the cross-regulation of PML and p53 and its fam-
ily members has reached the two-digit ﬁgure, with approximately
20 independently published studies. The take home message is
that PML controls the expression and activity of p53 and family
members through multiple mechanisms, including facilitating a
numberofpost-translationalmodiﬁcationsofp53andinteracting
with many factors that in turn regulate p53, p73, and p63 activity
(31–33). Recently, two independent papers conﬁrmed that PML
andp53alsofunctionallyinteractinvivo,aslossofPml contributes
signiﬁcantalternationsintumorphenotypesintwomousemodels
of p53-induced tumorigenesis (34, 35).
Bernardi: While I agree that this function of PML is the most
validated,IﬁndexcitingthatnewfunctionsofPMLarestillemerg-
ing, and I think that these new aspects of PML biology will be
greatly investigated in the future. I am referring to the role of
PML in stem cell biology and metabolism, which also relates to
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regulating the PI3K pathway, as you mentioned. Indications that
PML regulates the biology of stem cells have come recently from
two elegant and unrelated studies in which the function of PML
was investigated in leukemia and hematopoietic stem cells (36),
andinneuralstemcells(37).Intheﬁrstpaper,PMLwasdescribed
as an essential regulator of stem cell maintenance, both in nor-
mal hematopoiesis and in chronic myeloid leukemia, as deletion
of Pml in KO mice led to loss of quiescence and exhaustion of
hematopoietic and leukemia stem cells (36). Interestingly, inhibi-
tionof Pmlbyarsenictrioxidedisruptedmaintenanceof leukemia
initiating cells thus sensitizing leukemia to treatment with other
anti-leukemia agents (36). In the second paper,a thorough analy-
sis of the developing brain of Pml KO mice revealed that PML
suppresses proliferation and associates with the immature state of
neural progenitors by promoting cell cycle arrest (37).
As per the mechanisms involved in PML-regulated mainte-
nance of stem cell potential, an association of Pml loss with high
mTOR activity, in turn known to drive stem cell exhaustion, was
initially observed in hematopoietic stem cells (36). This obser-
vation further conﬁrmed previous work where we had described
PML as a negative regulator of mTOR activity in hypoxic con-
ditions, thus leading to inhibition of hypoxia-inducible factors
signaling and tumor neo-angiogenesis (38). I think that this is
also very much coherent with the fact that the hematopoietic
stem cell niche is known to be a hypoxic environment. More
recently, however, it was also shown that in hematopoietic stem
cells PML stimulates fatty acid metabolism (39), which in turn
regulatesstemcellmaintenanceandasymmetricstemcelldivision
at the expense of symmetric cell commitment (39). In the context
of neural stem cells, PML was implicated in a different mech-
anism of action, in line with its ability to maintain quiescence:
pRb-mediated regulation of cell cycle entry (37).
In summary, although a role for PML in regulating stem cell-
ness is emerging, mechanistically it is possible that PML regulates
stem cell maintenance through different mechanisms in differ-
ent tissues. In this respect, it should be mentioned that PML was
recently shown to also promote the expression of the stem cell
factor Oct4 in proliferating embryonic cells by regulating an open
chromatin state in its promoter (40).
Pandolﬁ:You rightly mention metabolism as the other emerg-
ing aspect of PML biology. The regulation of metabolism by PML
further complicates our simplistic perception of PML as a “good
guy”: the tumor suppressor for any stressful cellular condition.
Over the years, this notion had been very reassuring, and as you
know we are always reassured by simple models. However, PML,
which had been considered a tumor suppressor gene for over
20years, is now found to exert oncogenic functions in speciﬁc
tumor contexts precisely because of its metabolic role. We came
to the understanding that PML might also behave as an oncogene
while we were further investigating its role in regulating metabo-
lism (39).We had already shown in several important studies that
PMLregulatesatmultiplelevelsaveryimportantproto-oncogenic
pathway, the PI3K/PTEN/AKT/mTOR signal transduction path-
way, which is also critical in metabolism and metabolic home-
ostasis. We had found that PML opposes this pathway at multiple
levels:byfavoringPTENpropernuclearcytosolicshuttlingthough
its ability to oppose HAUSP deubiquitilation (41); by inactivating
nuclear Akt through dephosphorylation into the PML-NBs (42),
and by regulating nuclear accumulation and activity of mTOR in
conditions of hypoxia, thus impinging onto hypoxia-responsive
pathways (38).
More recently, however, we found that PML exerts another
important metabolic function by acting as a potent activator of
PPARsignalingandpositivelyregulatingfattyacidoxidation(39).
While this function of PML supports asymmetric cell division in
normal hematopoietic stem cells (39), it also inhibits cell death
by anoikis hence favoring cell survival in breast cancer cells (39).
Therefore, together with our previous identiﬁcation of PML as
a protective agents against leukemia stem cell exhaustion (36),
these new data reinforce the concept that in speciﬁc cell contexts
PML may also play oncogenic functions besides its best-known
tumor suppressive activities. Implications of these new data have
been recently discussed in two dedicated reviews (43, 44). Inter-
estingly, another study indicates that in Pml KO tissues a variety
of metabolic pathways are tissue-speciﬁcally de-regulated with
respect to wt animals, such as for instance glucose metabolism
and AMPK activation, thus suggesting that the role of PML in
regulating metabolism may go beyond the regulation of fatty acid
oxidation (45).
Bernardi: Certainly, the idea that PML has pro-oncogenic
functions in speciﬁc contexts is intriguing. Dual activities are
not unprecedented for oncogenes and tumor suppressors alike,
and it is plausible that different outcomes of PML expression
may be dictated by cell speciﬁc contexts. Indeed, although many
studies have documented loss of expression of PML in tumors
of different histological origin, more recently high expression
of PML has been reported in triple-negative breast cancer and
chronic myeloid leukemia (36, 39). A future challenge will be
to understand what are the discriminating genetic co-factors
of PML oncogenic or tumor suppressive functions and which
other, if any, tumor type might beneﬁt of PML tumor-promoting
functions.
In closing, tell me three aspects that excite you the most
regarding PML research in the next 20years.
Pandolﬁ: I would say: (i) PML regulation and function; (ii)
PML enzymatic activity;and (iii) implication for therapy,and not
necessarily in order of importance. Regarding PML regulation,we
have mentioned PML isoforms,but I think that there is a lot to be
learned by studying the mechanisms or post-transcriptional reg-
ulation of PML, and undoubtedly, additional functions of PML
will be uncovered in the future. Importantly, I think that we are
still scratching our heads concerning whether or not PML exerts a
distinctenzymaticactivity.WhileIamexcitedbytheessentialrole
that PML plays in the formation of the PML-NBs (11),I still hope
that there’s an enzymatic function of PML that we have failed to
discover thus far. A possible PML enzymatic activity, if any, will
prove extremely instructive of PML research in the years to come.
Lastly, I hope that collectively we will ﬁnd pharmacological ways
to modulate PML therapeutically for the treatment of cancer and
other disorders. This proved already critical to the eradication of
APL. We should never forget that one of the main reasons why
arsenic trioxide has led to APL cure is because it can target PML-
RAR and also PML for degradation (39, 46). I therefore think
that in the years to come PML research will pave the way to new
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discoveries and therapies for cancer and other diseases. So,we will
keep actively working on PML and you Rosa should do the same
in your lab!
Bernardi: I sure will.
ACKNOWLEDGMENTS
We wish to sincerely thank all current and past members of the
Pandolﬁ and Bernardi laboratories working on PML,as well as all
PML investigators whose discoveries have contributed to advance
the ﬁeld. This work was supported by NIH grants to Pier Paolo
Pandolﬁ and grants by Giovanni Armenise-Harvard Foundation,
Fondazione Cariplo, and Italian Association for Cancer Research
to Rosa Bernardi.
REFERENCES
1. PandolﬁPP,GrignaniF,AlcalayM,MencarelliA,BiondiA,LoCocoF,et al.Struc-
ture and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and
characterization of its retinoid-binding and transactivation properties. Onco-
gene (1991) 6(7):1285–92.
2. deTheH,LavauC,MarchioA,ChomienneC,DegosL,DejeanA.ThePML-RAR
alpha fusion mRNA generated by the t(15;17) translocation in acute promye-
locytic leukemia encodes a functionally altered RAR. Cell (1991) 66(4):675–84.
doi:10.1016/0092-8674(91)90113-D
3. KakizukaA,MillerWHJr,UmesonoK,WarrellRPJr,FrankelSR,MurtyVV,et al.
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia
fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991)
66(4):663–74. doi:10.1016/0092-8674(91)90112-C
4. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc
ﬁnger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science
(1991) 254(5036):1371–4. doi:10.1126/science.1720570
5. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, et al.
Role of PML in cell growth and the retinoic acid pathway. Science (1998)
279(5356):1547–51. doi:10.1126/science.279.5356.1547
6. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17)
translocation of acute promyelocytic leukaemia fuses the retinoic acid recep-
tor alpha gene to a novel transcribed locus. Nature (1990) 347(6293):558–61.
doi:10.1038/347558a0
7. LongoL,DontiE,MencarelliA,AvanziG,PegoraroL,AlimenaG,et al.Mapping
of chromosome 17 breakpoints in acute myeloid leukemias. Oncogene (1990)
5(10):1557–63.
8. BorrowJ,GoddardAD,SheerD,SolomonE.Molecularanalysisofacutepromye-
locytic leukemia breakpoint cluster region on chromosome 17. Science (1990)
249(4976):1577–80. doi:10.1126/science.2218500
9. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripar-
tite motif family identiﬁes cell compartments. EMBO J (2001) 20(9):2140–51.
doi:10.1093/emboj/20.9.2140
10. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM
motif. Oncogene (2001) 20(49):7223–33. doi:10.1038/sj.onc.1204765
11. Bernardi R, Pandolﬁ PP. Structure, dynamics and functions of promyelo-
cytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 8(12):1006–16.
doi:10.1038/nrm2277
12. Lallemand-Breitenbach V, de The H. PML nuclear bodies. Cold Spring Harb
Perspect Biol (2010) 2(5):a000661. doi:10.1101/cshperspect.a000661
13. Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadler M, et al.
PML protein expression in hematopoietic and acute promyelocytic leukemia
cells. Blood (1993) 82(6):1858–67.
14. Boisvert FM, Hendzel MJ, Bazett-Jones DP. Promyelocytic leukemia (PML)
nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol
(2000) 148(2):283–92. doi:10.1083/jcb.148.2.283
15. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA
damage and cellular stress. Bioessays (2004) 26(9):963–77. doi:10.1002/bies.
20089
16. Dellaire G, Eskiw CH, Dehghani H, Ching RW, Bazett-Jones DP. Mitotic accu-
mulations of PML protein contribute to the re-establishment of PML nuclear
bodies in G1. J Cell Sci (2006) 119(Pt 6):1034–42. doi:10.1242/jcs.02817
17. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A, et al.
Characterizationofendogenoushumanpromyelocyticleukemiaisoforms.Can-
cer Res (2006) 66(12):6192–8. doi:10.1158/0008-5472.CAN-05-3792
18. Brand P,Lenser T,Hemmerich P. Assembly dynamics of PML nuclear bodies in
living cells. PMC Biophys (2010) 3(1):3. doi:10.1186/1757-5036-3-3
19. Nisole S, Maroui MA, Mascle XH,Aubry M, Chelbi-Alix MK. Differential roles
of PML isoforms. Front Oncol (2013) 3:125. doi:10.3389/fonc.2013.00125
20. Lin HK, Bergmann S, Pandolﬁ PP. Cytoplasmic PML function in TGF-beta sig-
nalling. Nature (2004) 431(7005):205–11. doi:10.1038/nature02783
21. Giorgi C, Ito K, Lin HK, Santangelo C, Wieckowski MR, Lebiedzinska M, et al.
PML regulates apoptosis at endoplasmic reticulum by modulating calcium
release. Science (2010) 330(6008):1247–51. doi:10.1126/science.1189157
22. Shimada N, Shinagawa T, Ishii S. Modulation of M2-type pyruvate kinase
activity by the cytoplasmic PML tumor suppressor protein. Genes Cells (2008)
13(3):245–54. doi:10.1111/j.1365-2443.2008.01165.x
23. Jin G,WangYJ,Lin HK. Emerging cellular functions of cytoplasmic PML. Front
Oncol (2013) 3:147. doi:10.3389/fonc.2013.00147
24. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolﬁ PP.
PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell
Biol (2004) 6(7):665–72. doi:10.1038/ncb1147
25. Mattsson K, Pokrovskaja K, Kiss C, Klein G, Szekely L. Proteins associated with
thepromyelocyticleukemiageneproduct(PML)-containingnuclearbodymove
tothenucleolusuponinhibitionofproteasome-dependentproteindegradation.
Proc Natl Acad Sci U S A (2001) 98(3):1012–7. doi:10.1073/pnas.031566998
26. Condemine W, Takahashi Y, Le Bras M, de The H. A nucleolar targeting signal
in PML-I addresses PML to nucleolar caps in stressed or senescent cells. J Cell
Sci (2007) 120(Pt 18):3219–27. doi:10.1242/jcs.007492
27. MansourSL,ThomasKR,CapecchiMR.Disruptionoftheproto-oncogeneint-2
inmouseembryo-derivedstemcells:ageneralstrategyfortargetingmutationsto
non-selectable genes. Nature (1988) 336(6197):348–52. doi:10.1038/336348a0
28. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML
is induced by oncogenic ras and promotes premature senescence. Genes Dev
(2000) 14(16):2015–27. doi:10.1101/gad.14.16.2015
29. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, et al. The function of PML
in p53-dependent apoptosis. Nat Cell Biol (2000) 2(10):730–6. doi:10.1038/
35036365
30. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML
regulates p53 acetylation and premature senescence induced by oncogenic Ras.
Nature (2000) 406(6792):207–10. doi:10.1038/35018127
31. BernassolaF,OberstA,MelinoG,PandolﬁPP.Thepromyelocyticleukaemiapro-
teintumoursuppressorfunctionsasatranscriptionalregulatorofp63.Oncogene
(2005) 24(46):6982–6. doi:10.1038/sj.onc.1208843
32. Dobbelstein M, Strano S, Roth J, Blandino G. p73-induced apoptosis: a ques-
tion of compartments and cooperation. Biochem Biophys Res Commun (2005)
331(3):688–93. doi:10.1016/j.bbrc.2005.03.155
33. Bernardi R,PapaA,Pandolﬁ PP. Regulation of apoptosis by PML and the PML-
NBs. Oncogene (2008) 27(48):6299–312. doi:10.1038/onc.2008.305
34. PapaA,Cordon-Cardo C,Bernardi R,Pandolﬁ PP. Compound in vivo inactiva-
tionof Pmlandp53uncoversafunctionalinteractioninangiosarcomasuppres-
sion. Genes Cancer (2012) 3(9–10):599–603. doi:10.1177/1947601912473604
35. Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, Pandolﬁ PP, et al. Loss of
PML cooperates with mutant p53 to drive more aggressive cancers in a gender-
dependent manner. Cell Cycle (2013) 12(11):1722–31. doi:10.4161/cc.24805
36. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, et al.
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008)
453(7198):1072–8. doi:10.1038/nature07016
37. Regad T, Bellodi C, Nicotera P, Salomoni P. The tumor suppressor Pml regu-
lates cell fate in the developing neocortex. Nat Neurosci (2009) 12(2):132–40.
doi:10.1038/nn.2251
38. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, et al.
PML inhibits HIF-1alpha translation and neoangiogenesis through repression
of mTOR. Nature (2006) 442(7104):779–85. doi:10.1038/nature05029
39. Carracedo A, Weiss D, Leliaert AK, Bhasin M, de Boer VC, Laurent G, et al.
A metabolic prosurvival role for PML in breast cancer. J Clin Invest (2012)
122(9):3088–100. doi:10.1172/JCI62129
40. ChuangYS,HuangWH,Park SW,Persaud SD,Hung CH,Ho PC,et al. Promye-
locyticleukemiaproteininretinoicacid-inducedchromatinremodelingof Oct4
gene promoter. Stem Cells (2011) 29(4):660–9. doi:10.1002/stem.623
www.frontiersin.org February 2014 | Volume 4 | Article 23 | 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bernardi and Pandolﬁ The ﬁrst 20years of PML research
41. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, et al.
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-
PML network. Nature (2008) 455(7214):813–7. doi:10.1038/nature07290
42. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pan-
dolﬁ PP. Identiﬁcation of a tumour suppressor network opposing nuclear Akt
function. Nature (2006) 441(7092):523–7. doi:10.1038/nature04809
43. Mazza M, Pelicci PG. Is PML a tumor suppressor? Front Oncol (2013) 3:174.
doi:10.3389/fonc.2013.00174
44. Martin-Martin N, Sutherland JD, Carracedo A. PML: not all about tumor sup-
pression. Front Oncol (2013) 3:200. doi:10.3389/fonc.2013.00200
45. Cheng X,Guo S,LiuY,Chu H,Hakimi P,Berger NA,et al. Ablation of promye-
locytic leukemia protein (PML) re-patterns energy balance and protects mice
from obesity induced by a western diet. J Biol Chem (2013) 288(41):29746–59.
doi:10.1074/jbc.M113.487595
46. DosSantosGA,KatsL,PandolﬁPP.SynergyagainstPML-RARa:targetingtran-
scription, proteolysis, differentiation, and self-renewal in acute promyelocytic
leukemia. J Exp Med (2013) 210(13):2793–802. doi:10.1084/jem.20131121
ConﬂictofInterestStatement:Theauthorsdeclarethattheresearchwasconducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 09 January 2014; accepted: 27 January 2014; published online: 10 February
2014.
Citation: Bernardi R and Pandolﬁ PP (2014) A dialog on the ﬁrst 20years of PML
research and the next 20 ahead. Front. Oncol. 4:23. doi: 10.3389/fonc.2014.00023
This article was submitted to Molecular and Cellular Oncology,a section of the journal
Frontiers in Oncology.
Copyright © 2014 Bernardi and Pandolﬁ. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Oncology | Molecular and Cellular Oncology February 2014 | Volume 4 | Article 23 | 6